Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.27373 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validated HPLC-UV Method for the Quantification of a Novel BCr-Abl 1 Inhibitor, Vodobatinib, in Rat Plasma: Application to a Pharmacokinetic Study.
Biomed Chromatogr
February 2025
Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd., Shamirpet, Hyderabad, India.
Vodobatinib is a Bcr-Abl 1 inhibitor, currently entering into Phase 2 clinical trials as a potential drug to treat glioblastoma patients. In the present work, a validated high-performance liquid chromatography (HPLC) detection method for the quantification of vodobatinib in rat plasma was established. Sample preparation involved liquid-liquid extraction method.
View Article and Find Full Text PDFDevelopment and alpha-testing of a patient decision aid for patients with chronic myeloid leukemia regarding dose reduction.
BMC Med Inform Decis Mak
December 2024
Department of Pharmacy, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.
Background: Dose reduction of tyrosine kinase inhibitors (TKIs) is an option for some chronic myeloid leukemia (CML) patients to minimize side effects while maintaining efficacy. Shared decision-making (SDM) and patient decision aids (PDAs) are advocated to make informed choices such as reducing the dose of TKIs. This paper describes the development and alpha-testing of a PDA for patients with CML receiving TKI dose reduction.
View Article and Find Full Text PDF[The role of cytogenetic tests in the diagnosis of malignant hematologic diseases].
Magy Onkol
December 2024
Laboratóriumi Medicina Intézet, Debreceni Egyetem, Általános Orvostudományi Kar, Klinikai Genetikai Tanszék, Debrecen, Hungary.
In malignant hematological diseases, clonal genetic alterations, such as chromosomal aberrations and gene mutations, are responsible for the uncontrolled division of abnormal hemopoietic cells. The detection of clonal variants has not only diagnostic, but also prognostic and therapeutic significance. They enable risk-based differentiated treatment of patients and the use of targeted (genotype-specific) therapies.
View Article and Find Full Text PDFMolecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasm in a Moroccan Population.
Asian Pac J Cancer Prev
November 2024
Cytogenetics Laboratory, Pasteur Institute of Morocco (IPM), 1 Place Louis Pasteur, 20360 Casablanca, Morocco.
Introduction: Myeloproliferative neoplasms (MPN) are associated with clonal hematopoiesis, genomic instability, hemostasis dysregulation, and immune response. Classic BCR-ABL1 negative myeloproliferative neoplasms (BCR-ABL1 negative MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are frequently associated with somatic abnormalities in JAK2, CALR, and MPL. Mutant clones induce an inflammatory immune response leading to immuno-thrombosis.
View Article and Find Full Text PDFNavigating diagnostic dilemmas: a rare presentation of extramedullary T-lymphoblastic leukemia/lymphoma with chronic myeloid leukemia.
J Hematop
December 2024
Department of Pathology, Microbiology, and Immunology University of Nebraska Medical Center, Omaha, NE, USA.
Chronic myeloid leukemia (CML) typically presents in the chronic phase. The blast crisis phase in CML predominantly comprises the myeloid phenotype, while B-cell lymphoblastic crisis is common among the lymphoid lineages. Presentation as a T-lymphoblastic crisis is exceptionally rare.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!